Literature DB >> 23832663

Tumor growth control with IDO-silencing Salmonella--reply.

Edwin R Manuel, Bruce R Blazar, Don J Diamond.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23832663      PMCID： PMC3804125          DOI： 10.1158/0008-5472.CAN-13-1274

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  10 in total

1.  Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium.

Authors:  C Clairmont; K C Lee; J Pike; M Ittensohn; K B Low; J Pawelek; D Bermudes; S M Brecher; D Margitich; J Turnier; Z Li; X Luo; I King; L M Zheng
Journal:  J Infect Dis       Date:  2000-06-05       Impact factor: 5.226

2.  Indoleamine 2,3-dioxygenase 1 is a lung-specific innate immune defense mechanism that inhibits growth of Francisella tularensis tryptophan auxotrophs.

Authors:  Kaitian Peng; Denise M Monack
Journal:  Infect Immun       Date:  2010-04-12       Impact factor: 3.441

Review 3.  Interferons and indoleamine 2,3-dioxygenase: role in antimicrobial and antitumor effects.

Authors:  J M Carlin; Y Ozaki; G I Byrne; R R Brown; E C Borden
Journal:  Experientia       Date:  1989-06-15

4.  Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma.

Authors:  John F Toso; Vee J Gill; Patrick Hwu; Francesco M Marincola; Nicholas P Restifo; Douglas J Schwartzentruber; Richard M Sherry; Suzanne L Topalian; James C Yang; Frida Stock; Linda J Freezer; Kathleen E Morton; Claudia Seipp; Leah Haworth; Sharon Mavroukakis; Donald White; Susan MacDonald; John Mao; Mario Sznol; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2002-01-01       Impact factor: 44.544

5.  Enhancement of cancer vaccine therapy by systemic delivery of a tumor-targeting Salmonella-based STAT3 shRNA suppresses the growth of established melanoma tumors.

Authors:  Edwin R Manuel; Céline A Blache; Rebecca Paquette; Teodora I Kaltcheva; Hidenobu Ishizaki; Joshua D I Ellenhorn; Michael Hensel; Leonid Metelitsa; Don J Diamond
Journal:  Cancer Res       Date:  2011-04-28       Impact factor: 12.701

6.  Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium.

Authors:  Ming Zhao; Meng Yang; Xiao-Ming Li; Ping Jiang; Eugene Baranov; Shukuan Li; Mingxu Xu; Sheldon Penman; Robert M Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-11       Impact factor: 11.205

7.  Bacterial delivery of a novel cytolysin to hypoxic areas of solid tumors.

Authors:  R M Ryan; J Green; P J Williams; S Tazzyman; S Hunt; J H Harmey; S C Kehoe; C E Lewis
Journal:  Gene Ther       Date:  2009-01-29       Impact factor: 5.250

8.  Systemic delivery of Salmonella typhimurium transformed with IDO shRNA enhances intratumoral vector colonization and suppresses tumor growth.

Authors:  Céline A Blache; Edwin R Manuel; Teodora I Kaltcheva; Andrea N Wong; Joshua D I Ellenhorn; Bruce R Blazar; Don J Diamond
Journal:  Cancer Res       Date:  2012-10-22       Impact factor: 12.701

9.  Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients.

Authors:  John Nemunaitis; Casey Cunningham; Neil Senzer; Joseph Kuhn; Jennifer Cramm; Craig Litz; Robert Cavagnolo; Ann Cahill; Caroline Clairmont; Mario Sznol
Journal:  Cancer Gene Ther       Date:  2003-10       Impact factor: 5.987

10.  Salmonella typhimurium engineered to produce CCL21 inhibit tumor growth.

Authors:  Markus Loeffler; Gaelle Le'Negrate; Maryla Krajewska; John C Reed
Journal:  Cancer Immunol Immunother       Date:  2008-07-17       Impact factor: 6.968
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.